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CO R R E S POND EN C E : O U R E X P E R I E N C E
Laryngeal candidiasis: Our experience from sixty biopsy
specimens
1 | INTRODUCTION
Persistent throat symptoms, such as dysphonia, globus and throat
pain, are highly prevalent and are a significant cause of morbidity.1
In a number of cases, a clear cause of these symptoms is not identi-
fied, and many patients are treated empirically with lifestyle advice
and/or anti-reflux medication.2
There is an increasing frequency of respiratory diseases, such as
asthma and chronic obstructive pulmonary disease (COPD), with
associated increased use of inhaled corticosteroids (ICS).3 Oropharyn-
geal candidiasis is a well-recognised complication of ICS, particularly
when inhaler technique and oropharyngeal hygiene are poor.4 There
is, however, limited evidence on the prevalence of laryngeal candidia-
sis in those taking ICS.5 While clinical diagnosis is sometimes possi-
ble, it has been highlighted in oropharyngeal candidiasis that clinical
findings do not always correlate with the presence of fungi.6,7
We hypothesised that laryngeal candidiasis may be an under-
recognised cause of laryngeal inflammation and persistent throat
symptoms in a subgroup of patients presenting to ENT clinics, partic-
ularly those taking ICS. We therefore aimed to retrospectively
review the presence of candidiasis in a series of laryngeal biopsies.
2 | METHODS
We retrospectively reviewed the laryngeal biopsy samples and case
notes of patients presenting to the ENT outpatients department of
the Newcastle upon Tyne Hospitals NHS Foundation Trust. We
identified a series of patients who had previously undergone laryn-
geal biopsy for persistent throat symptoms and had suspicious find-
ings on flexible endoscopy and had documented current ICS use.
We also identified from the same database of biopsy samples an age
and sex-matched group of patients without respiratory co-morbid-
ities or documented ICS use.
Patients were included if (i) there was no visual evidence of can-
didiasis documented following laryngeal examination under general
anaesthesia (EUA) and (ii) the biopsy samples demonstrated no evi-
dence of epithelial dysplasia or malignancy.
For patients fulfilling the study inclusion criteria, the formalin-
fixed paraffin-embedded tissue samples were retrieved from the
pathology archive, and three 4 lm sections were cut into superfrost
microscope slides. The sections were then stained with diastase peri-
odic acid schiff (DPAS) reagent to identify fungal hyphae. The DPAS
staining was carried out in a clinical pathology accreditation (CPA)
endorsed cellular pathology laboratory. A specialist head and neck
pathologist (TJB or MR) then reviewed the sections and reported on
any evidence of candidiasis.
2.1 | Statistical analysis
All clinical data were sorted on secure NHS computers, and analysis
was performed on Microsoft Excel 14.6.5 (Redmond, Washington,
USA).
2.2 | Ethical considerations
The project was registered with the Clinical Governance Department
of the Newcastle upon Tyne Hospitals NHS Foundation Trust. Jason
Powell was funded by a clinical research fellowship: WT108768MA
Wellcome Trust.
3 | RESULTS
Thirty patients were identified who had documented use of ICS and
met our inclusion criteria (mean age 60  4.6 years old [95% confi-
dence interval]; male:female ratio 7:23). We identified 30 age and
sex-matched patients without documented respiratory co-morbidities
or ICS use, who had biopsies taken between January 2010 and July
2015. The most common indication for biopsy for patients in both
groups was for non-specific signs of inflammation (ICS group 15 of
30, non-ICS group 14 of 30). The rest were for other benign causes,
such as cysts or Reinke’s oedema. Of the patients with documented
ICS use, 15 of 30 initially presented primarily with dysphonia, 5 of
30 with persistent sore throat and 4 of 30 with globus. The remain-
ing 6 of 30 presented with a combination of other symptoms, such
as cough. The respiratory co-morbidities included 16 of 30 with
COPD, 11 of 30 with asthma and the remaining 3 of 30 had a com-
bination of the two or bronchiectasis.
In the ICS group, only 2 of 30 previously had a DPAS staining
performed by the pathology laboratory. Both were found to be neg-
ative, as in our assessment. Review of the pathology request cards
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demonstrated that only one patient had a respiratory co-morbidity
documented and none had the use of ICS documented by the
requesting clinician.
Our DPAS testing of laryngeal samples demonstrated that overall
9 of 60 patients (15%) had evidence of fungal hyphae, consistent
with candidiasis (see Figure 1). Candidal hyphae were found more
frequently in those taking ICS (6 of 30, 20%), compared with the age
and sex-matched patients not taking ICS (3 of 30, 10%, 3 were all
female).
4 | DISCUSSION
4.1 | Synopsis of key findings
Candidiasis was a surprisingly common finding in our series of
laryngeal biopsy samples. These patients had no indication of
laryngeal candidiasis on EUA and no evidence of malignancy. Can-
didiasis was apparently more common in patients taking ICS, when
compared to age and sex-matched controls. Laryngeal candidiasis
may represent a potentially treatable cause for persistent throat
symptoms in some patients. However, further studies would be
required to fully assess whether the candidiasis caused these
symptoms.
Notably, almost all of the biopsy samples taken from patients
with ICS use were not initially tested for candidiasis by the
pathology laboratory. Disclosure of ICS status or respiratory co-mor-
bidities was almost universally absent from the clinical documenta-
tion in the pathology request form.
4.2 | Strengths and weaknesses of the study
This is a small retrospective study and subjects to several limitations.
Firstly, the documentation of ICS may be unreliable, and it is con-
ceivable that some of the non-ICS use group were actually ICS users.
DPAS is used for visualising the carbohydrate components of can-
dida and as with any interpretive test will have limitations and the
potential for reporter error. There are no guidelines on how many
sections to stain when performing DPAS testing. DPAS is able to
identify the glycoprotein content of fungi, although it may not be
able to distinguish small early fungal stages due to their size or
indeed specific candida species. The samples were all tested in a
quality-assured CAP-endorsed pathology laboratory and reported by
a specialist head and neck pathologist.
We present a relatively elderly cohort of patients reflecting the
indications for laryngeal biopsies and need to exclude malignancy.
There is a possibility post-menopausal hormone changes may affect
candida colonisation on laryngeal mucosa secondary to pH influ-
ences. This limits our conclusions with regard to the incidence of
laryngeal candida in younger ICS users.
We were also unable to perform subgroup analysis of the EUA
findings (such as inflammation or cysts) and the presence or the
absence of laryngeal candidiasis due to the small study numbers.
Similarly, we are not able to distinguish in this study whether throat
symptoms are specifically due to candida infection or due to other
benign pathologies such as Reinke’s oedema or cysts. Furthermore, it
would be ideal to compare the prevalence of candida in a control
group of ICS users without throat symptoms. However, we would
not routinely be taking laryngeal biopsies from normal larynx in
patients without such symptoms. Observational evidence from this
pilot study will assist in planning studies that further consider
asymptomatic patients, adequate power and causality rather than
correlation.
(A)
(B)
F IGURE 1 Laryngeal vocal cord biopsy stained with Diastase
Periodic Acid Schiff (DPAS) at 920 magnification. A, DPAS negative
sample without fungal hyphae (920 magnification). B, DPAS positive
sample with magenta-coloured fungal hyphae
Keypoints
• Candidiasis was found in a number of laryngeal biopsy
specimens tested. These patients had no reported visual
evidence of candidiasis on laryngoscopy.
• Laryngeal candidiasis was more commonly identified in
the pathology samples of those with documented use of
inhaled corticosteroid therapy (20%) than those without
documented use (10%).
• Local discussion between otolaryngologists and patholo-
gists on the testing of laryngeal samples for candidiasis is
required to ensure appropriate investigations are per-
formed in a standardised manner.
2 | CORRESPONDENCE: OUR EXPERIENCE
4.3 | Comparison with other studies
The potential of laryngeal candidiasis to cause persistent throat
symptoms is supported by Wong et al8 who reported that dysphonia
was present in as many as 37 of 54 (69%) of patients with diag-
nosed laryngeal candidiasis. Turan et al9 reported a similar rate of
laryngeal candidiasis to our study of 17.9% in 39 patients using ICS.
From the oropharyngeal candidiasis literature, a study of 15 patients
taking ICS for asthma found rates as high as 50% for pharyngeal
yeast-positive culture.6 Supporting our findings, it was noted that
the presence of yeast did not always correlate with the clinical find-
ings. Furthermore, in a review of 223 oral lesion biopsies, 4.7% of
biopsies were positive for fungi on DPAS staining despite a lack of
clinical signs of candida.7
4.4 | Clinical applicability of the study
We have identified notable rates of laryngeal candidiasis, via DPAS
testing of pathology samples, in a cohort of ICS users, and also
high rates in those without a clear documentation of ICS use.
These patients presented to ENT clinics with persistent throat
symptoms and endoscopic findings of inflammation, without evi-
dence of malignancy. It could be hypothesised that their symptoms
may have been caused by this infection. However, there are many
causes of persistent throat symptoms, not least ICS themselves,
which are known to cause laryngeal irritation and inflammation.5 A
larger, adequately powered, study assessing response to treatment
is required to confirm the findings from our case series and investi-
gate causality.
There are several key questions to answer in future studies.
These include: does ICS cause laryngeal candidiasis, does laryngeal
candidiasis causes throat symptoms, what is the effect of fungal
stage on laryngeal inflammation and what is the effect of topical
antifungal treatment on throat symptoms in ICS users? Further-
more, an important question remains regarding the impact of pro-
ton pump inhibitors on laryngeal candidiasis. Proton pump
inhibitors appear to have a direct inhibitory effect of the H+-
ATPase enzyme activity native to fungi.10 They also have an indi-
rect pH effect via alkalinisation, which affects the local aero-diges-
tive micro-environment. These effects are likely to have impacts
on both candida growth/colonisation and candida morphogenesis,
by favouring a potentially pathogenic hyphal stage. Finally, it is yet
not fully defined what the role of systemic antifungal treatment is
in laryngeal candidiasis. Our experience with oesophageal candidia-
sis suggests that it does indeed have a role, especially in immuno-
compromised individuals. Given the increasing rates of ICS use
worldwide and the socio-economic impact of persistent throat
symptoms, identification of a potentially treatable cause would be
highly advantageous.2,3
An important consideration is that routine histological practice in
our unit is not to perform DPAS testing without clinical or histologi-
cal indications of potential candidiasis. While the practice is variable
amongst pathologists, it is crucial for otolaryngologists to document
clinical suspicion of candidiasis and/or ICS use on pathology request
forms to ensure full testing of laryngeal samples. Development of
local and national guidelines for when to perform DPAS histochem-
istry would also be of benefit. Furthermore, we recommend spacer
units for patients taking ICS to reduce the rate of candidiasis in the
upper aero-digestive tract. Greater understanding of the incidence of
laryngeal candidiasis could aid clinical decision-making which justifies
further studies on this topic.
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